J Korean Med Sci.  2020 Aug;35(33):e311. 10.3346/jkms.2020.35.e311.

Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea

• Noh JY
• Seo YB
• Yoon JG
• Seong H
• Hyun H
• Lee J
• Lee N
• Jung S
• Park MJ
• Song W
• Yoon J
• Lim CS
• Ryou J
• Lee JY
• Kim SS
• Cheong HJ
• Kim WJ
• Yoon SY
• Song JY

• KMID: 2505601
• DOI: http://doi.org/10.3346/jkms.2020.35.e311

Abstract

Serosurveillance studies reveal the actual disease burden and herd immunity level in the population. In Seoul, Korea, a cross-sectional investigation showed 0.07% anti-severe acute respiratory syndrome coronavirus-2 antibody seropositivity among 1,500 outpatients of the university hospitals. Low seroprevalence reflects well-implemented social distancing. Serosurveillance should be repeated as the pandemic progresses.

Keyword

Seroprevalence; Seroepidemiology; SARS-CoV-2; COVID-19

Figure

• 

  Fig. 1 Map of study site with study hospitals marked in blue. Sites of clusters of coronavirus disease outbreaks near the study hospitals are shown in red: ⓐ sports club, ⓑ call center, ⓒ church, ⓓ distribution center. The COVID-19 outbreak in a sport club (ⓐ) was detected on Jun 5, 2020, and visitors at the sport club from May 28 to June 2, 2020 were investigated. A call center (ⓑ) outbreak was first detected on March 9, 2020. Outbreak in a church (ⓒ) was detected on March 26, 2020 and outbreak at the distribution center (ⓓ) was detected on May 25, 2020.

• 

  Fig. 2 Number of cases of coronavirus disease as of July 3, 2020 in Korea. Study samples were collected from May 25 to May 29, 2020 (indicated with an arrow).

Reference

1. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020; 382(12):1177–1179. PMID: 32074444.

2. Noh JY, Yoon JG, Seong H, Choi WS, Sohn JW, Cheong HJ, et al. Asymptomatic infection and atypical manifestations of COVID-19: comparison of viral shedding duration. J Infect. 2020; S0163-4453(20)30310-8.

3. Lee YH, Hong CM, Kim DH, Lee TH, Lee J. Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerg Infect Dis. 2020; 26(10):

4. World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection. Updated 2020. Accessed July 5, 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2.

5. Ministry of Health and Welfare (KR). Coronavirus disease-19, Republic of Korea. Updated 2020. Accessed July 5, 2020. http://ncov.mohw.go.kr/.

6. Roche. Elecsys^® Anti-SARS-CoV-2. Updated 2020. Accessed August 9, 2020. https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html.

7. Seoul Metropolitan Government. Statistics of registered foreigners in Seoul (by nationality/administrative district). Updated 2020. Accessed July 5, 2020. https://data.seoul.go.kr/dataList/803/S/2/datasetView.do?tab=C#.

8. Seoul Metropolitan Government. Statistics of Seoul resident registered population (by administrative district). Updated 2020. Accessed August 9, 2020. https://data.seoul.go.kr/dataList/419/S/2/datasetView.do.

9. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020; 26(8):1193–1195. PMID: 32504052.

10. Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study. medRxiv. Updated 2020. Accessed July 7, 2020. DOI: 10.1101/2020.04.26.20079822.

11. To KK, Cheng VC, Cai JP, Chan KH, Chen LL, Wong LH, et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet Microbe. 2020; 1(3):E111–8.

12. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles County, California, on April 10-11, 2020. JAMA. 2020; 323(23):2425–2427.

13. Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill. 2020; 25(24):2001031.

14. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020; 396(10247):313–319. PMID: 32534626.

15. Slot E, Hogema BM, Reusken CB, Reimerink JH, Molier M, Karregat JH, IJlst J, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. Res Sq. Updated 2020. Accessed July 7, 2020. DOI: 10.21203/rs.3.rs-25862/v1.

16. Habib H. Has Sweden's controversial COVID-19 strategy been successful? BMJ. 2020; 369:m2376. PMID: 32532807.

17. Public Health Agency of Sweden. Första resultaten från pågående undersökning av antikroppar för COVID-19-virus. Updated 2020. Accessed July 7, 2020. https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus/.

18. Song SK, Lee DH, Nam JH, Kim KT, Do JS, Kang DW, et al. IgG Seroprevalence of COVID-19 among individuals without a history of the coronavirus disease infection in Daegu, Korea. J Korean Med Sci. 2020; 35(29):e269. PMID: 32715672.

19. Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, et al. Serodiagnostics for severe acute respiratory syndrome-related coronavirus-2: a narrative review. Ann Intern Med. 2020; M20-2854.